What is the cause of a Coccidioides (Cocci) rash in Valley fever?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Valley fever rash is typically managed with antifungal medications such as fluconazole (400-800 mg daily) for 3-6 months in symptomatic cases, and the rash itself may be managed with antihistamines for itching or anti-inflammatory medications for discomfort. The rash associated with Valley fever usually appears as red bumps, nodules, or painful red lumps called erythema nodosum, usually on the lower legs 1. Some patients may develop a more widespread rash that can be flat or raised, sometimes with blisters. If you develop a rash along with fever, cough, fatigue, headache, or joint pain, especially after being in an endemic area like Arizona or California, seek medical attention promptly.

Treatment Considerations

  • The recommended dose of fluconazole is 400 mg daily, although some panel members would use up to 800 mg daily 1.
  • The recommended dose of itraconazole is 200 mg twice daily 1.
  • Treatment duration is typically at least 6-12 months due to high relapse rates 1.
  • For patients with concurrent diabetes or who are otherwise frail because of age or comorbidities, initiating antifungal treatment is recommended 1.

Disease Overview

Valley fever is caused by inhaling spores of the fungus Coccidioides, which primarily affects the lungs but can disseminate to the skin and other organs in some cases. The rash represents the body's immune response to the fungal infection and typically improves as the underlying infection is treated. Soft tissue coccidioidomycosis can be divided into skin lesions, subcutaneous abscesses, and distant soft tissue sites, with cutaneous granulomatous lesions being the most benign form of coccidioidal dissemination 1.

Management Approach

In general, oral azoles have become the treatment of choice due to lower toxicity and convenience of administration 1. Prospective trials of azole therapy for skin and soft tissue coccidioidomycosis report response rates ranging from 25% to 91%, with relapse rates ranging from 60% after 45 days of therapy, to 11% after 12 months 1. For most patients, treatment with antifungal medications and management of symptoms is the primary approach to managing Valley fever rash.

From the Research

Valley Fever Rash

  • Valley fever, also known as coccidioidomycosis, is a fungal infection caused by the inhalation of Coccidioides endospores 2.
  • The symptoms of coccidioidomycosis include fever, erythema nodosum, and arthralgia, often accompanied by a respiratory problem 2.
  • A rash can be a symptom of Valley fever, with erythema nodosum being a common manifestation 2, 3.
  • The diagnosis of coccidioidomycosis is typically made through a combination of clinical evaluation, antibody tests, and microscopy to directly detect the presence of Coccidioides in a patient tissue sample 2.
  • Treatment for Valley fever typically involves symptomatic treatment, with antifungal medications such as azoles or amphotericin B used in more severe cases 2, 3, 4, 5.

Treatment Considerations

  • The treatment of coccidioidomycosis varies depending on the immunocompetency of the patient, with pregnant patients and those with a history of HIV or transplantation requiring special considerations 2, 3, 5.
  • Fluconazole is a commonly used antifungal medication for the treatment of pulmonary coccidioidomycosis 2, 3, 5.
  • Other antifungal medications, such as voriconazole and posaconazole, may be used as salvage treatment for refractory coccidioidomycosis 4.
  • The treatment of fungal pneumonias, including coccidioidomycosis, is a major concern in immunocompromised patients, and clinicians should consider the most appropriate and aggressive treatment approach 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

THE TREATMENT OF COCCIDIOIDOMYCOSIS.

Revista do Instituto de Medicina Tropical de Sao Paulo, 2015

Research

Treatment of refractory coccidioidomycosis with voriconazole or posaconazole.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011

Research

Treatment considerations in pulmonary coccidioidomycosis.

Expert review of respiratory medicine, 2016

Research

Recommendations for the treatment of fungal pneumonias.

Expert opinion on pharmacotherapy, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.